Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice

Annals of the New York Academy of Sciences

Volumn 965, Issue , 2002, Pages 274-280

  Chera, Bhisham ^a   Schaecher, Kurt E ^a,c   Rocchini, Anne ^a   Imam, Syed Z ^b   Ray, Swapan K ^a   Ali, Syed F ^b   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c Department of Microbiology and Immunology   (United States)

Author keywords

Apoptosis; Astrocyte; Dopaminergic neurons; Motor neuron; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDRO 1 METHYL 4 PHENYLPYRIDINIUM; CALPAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL NUCLEUS MEMBRANE; CELL STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; IMMUNOFLUORESCENCE; MALE; MOUSE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; SPINAL CORD; SUBSTANTIA NIGRA; TREMOR;

ANIMALIA;

EID: 0036291490     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04169.x     Document Type: Conference Paper

References (43)

1. Pathophysiology of parkinsonian motor abnormalities
2. Etiology and pathogenesis of Parkinson's disease
3. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease
4. Familial Parkinson's diseases. The awakening of alpha-synuclein [news]
5. The ubiquitin/proteosome pathway in neurological disorders
6. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydroxylase gene in familial Parkinson's disease
7. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry
8. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease
9. Motor neuron disease, parkinsonism and dementia. Report of a case with diffuse Lewy body-like intracytoplasmic inclusions
10. Systemic administration of MPTP induces thalamic neuronal degeneration in mice
11. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice
12. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
13. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
14. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
15. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin
16. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
17. Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain
18. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
19. Mitochondrial complex 1 deficiency in Parkinson's disease
20. Oxidation reactions in Parkinson's disease
21. Role of mitochondria in Parkinson disease
22. Parkinson's disease: A disorder due to nigral glutathione deficiency?
23. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
24. Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice
25. Calpain
26. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus
27. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP
28. Catecholaminergic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease
29. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients
30. Evidence for the role of spinal cord systems in Parkinson's disease-associated pain
31. Spinal cord inhibitory mechanisms in Parkinson's disease
32. Spinal dopamine mechanisms and primary sensory symptoms in Parkinson's disease
33. An electrophysiological study of the functional changes in the spinal motoneurones in Parkinson's disease
34. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: A role in nerve cell death?
35. Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease
36. Combined TUNEL and double immunofluorescence labeling for detecting apoptotic mononuclear phagocytes in autoimmune demyelinating disease
37. Calcium-activated neutral proteinase in demyelinating diseases
38. Calcium-activated neutral protease (calpain) system: Structure, function, and regulation
39. Calcium-activated neutral protease and its endogenous inhibitor. Activation at the cell membrane and biological function
40. Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells
41. 2+ influx upregulate calpain and induce apoptosis in PC12 cells
42. A putative mechanism of demyelination in multiplesclerosis by a proteolytic enzyme, calpain
43. Deficit in a Krebs cycle mitochondrial enzyme in brains from patients with Parkinson's disease